| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 11 | 268.5x | 17.8x | Bottom tier | |
Growth | 63 | 16.0% | 7.1% | Around median | |
Quality | 82 | 5.1% | 4.5% | Top tier | |
Safety | 95 | — | 2.6x | Top tier | |
Capital Return | 28 | — | 2.12% | Bottom tier | |
Momentum | 93 | 58.9% | 2.9% | Top tier | |
Sentiment | 24 | 4 | 3 | Bottom tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Corcept Therapeutics develops drugs that modulate cortisol activity by targeting the glucocorticoid receptor to treat serious endocrine and oncology diseases, with additional clinical programs in MASH, ALS, and multiple solid tumors. The company generates commercial revenue from Korlym and its authorized generic for the treatment of Cushing's syndrome, and from Lifyorli for the treatment of platinum-resistant ovarian cancer; in fiscal Q2 2026, revenue from Korlym and the authorized generic reached $208.6 million, compared with $47.6 million from Lifyorli in its first quarter of availability.
Fiscal Q2 2026 revenue was approximately $256.1 million, up 32% from the comparable period according to the earnings call, and gross profit was $252.1 million, equivalent to a gross margin of approximately 98.4%. Cushing's syndrome products represented approximately 81.5% of quarterly revenue, while Lifyorli represented approximately 18.6%, and the company reported net income of $43.0 million and earnings per share of $0.36, compared with net income of $35 million in the comparable period.
Fiscal 2025 results show revenue of $761.4 million, gross profit of $748.4 million, and net income of $99.7 million. As of June 30, 2026, the company held $545 million in cash and investments, while management said operating expenses in fiscal Q2 2026 remained stable compared with fiscal Q1 2026, which recorded a net loss of $31.8 million.
The consensus average analyst price target is $125.33, which is close to the upper end of the 52-week range of $126.38, while the consensus rates the stock a “Buy.” However, the disparity between the lowest target of $50 and the highest target of $165 is wide, and no reported price-to-earnings ratio is available despite a market capitalization of $12.3 billion; therefore, the valuation is closely tied to continued growth in Korlym and Lifyorli, the FDA's decision on relacorilant, and development pipeline results.
Figures in the text are as of 2026-08-29; the live price is shown at the top of the page.
Corcept's fiscal Q2 2026 revenue was approximately $256.1 million, up 32% from the comparable period. Korlym and the authorized generic contributed $208.6 million, and Lifyorli added $47.6 million in its first quarter of availability. Based on the strength of the endocrine and oncology businesses, management raised fiscal 2026 revenue guidance to between $1.1 billion and $1.2 billion.
The FDA approved Lifyorli on March 25, 2026, and the company began selling its capsules on April 1, 2026, for the treatment of platinum-resistant ovarian cancer. The drug generated $47.6 million in revenue in fiscal Q2 2026, and more than 1,300 patients had started treatment by the July 29, 2026 call. More than 1,000 physicians had also prescribed it, and formal coverage policies were in place for more than 70% of people covered collectively by Medicare, Medicaid, and commercial insurance.
ROSELLA tested Lifyorli with nab-paclitaxel chemotherapy in patients with platinum-resistant ovarian cancer. The treatment met both primary endpoints by delaying disease progression and extending overall survival to a statistically significant degree. The risk of death was reduced by 35%, with a hazard ratio of 0.65 and a p-value of 0.04, and the benefit appeared without requiring a biomarker for patient selection.
Automated analysis for informational purposes only — not investment advice.
Corcept resubmitted the New Drug Application for relacorilant for the treatment of Cushing's syndrome on June 17, 2026, following the Complete Response Letter it received at the end of 2025. The FDA accepted the resubmission and set December 17, 2026, as the decision date. The application is based on the pivotal phase 3 GRACE trial, with supporting evidence from the phase 3 GRADIENT trial, the long-term extension study, and data from earlier phases.
CATALYST found that 24% of screened patients with difficult-to-treat diabetes had hypercortisolism, rising to 39.7% among those who had both resistant diabetes and resistant hypertension. MOMENTUM screened more than 1,000 patients whose blood pressure was not controlled despite using three or more medications and found hypercortisolism in 27% of them, with a rate of 32.6% among those who also had resistant diabetes. CATALYST results were published in Diabetes Care in 2025 and referenced in AACE guidelines in March 2026, while MOMENTUM was presented at the ACC conference in March 2026 and the ADA conference in June 2026.
The BELLA, STELLA, and TRIDENT studies are testing relacorilant in ovarian, endometrial, cervical, and pancreatic cancers, and management said their results will be released by the end of 2027. SYNERGY is testing miricorilant with nivolumab across a broad range of solid tumors, while the phase 2b MONARCH study targets MASH and has completed enrollment of 175 patients. In ALS, DAZZLE showed an 87% reduction in the risk of death in the second year with a 300 mg dose of dazicorilant, but the company is studying dose optimization because of gastrointestinal adverse events that caused most withdrawals.
